-
公开(公告)号：US20220162598A1
公开(公告)日：2022-05-26
申请号：US16869126
申请日：2020-05-07
Applicant: WAVE LIFE SCIENCES LTD.
Inventor： Chandra Vargeese , Meena , Nenad Svrzikapa , Susovan Mohapatra , Christopher J. Francis , Gregory L. Verdine , Anna Sokolovska
IPC: C12N15/11 , C12N15/113
Abstract: Among other things, the present disclosure relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer. In some embodiments, a chirally controlled oligonucleotide composition has any sequence of bases, and/or pattern or base modifications, sugar modifications, backbone modifications and/or stereochemistry, or combination of these elements, described herein.
-
公开(公告)号：US20160347784A1
公开(公告)日：2016-12-01
申请号：US15167669
申请日：2016-05-27
Applicant: WAVE LIFE SCIENCES LTD.
Inventor： Gregory L. Verdine , Meena , Naoki Iwamoto
IPC: C07H21/00
CPC classification number: A61K31/70 , C07F9/65515 , C07H21/00
Abstract: Described herein are nucleic acid prodrugs and nucleic acid prodrugs comprising chiral phosphorous moieties. Also described herein are methods of making and using nucleic acid prodrugs and nucleic acid prodrugs comprising chiral phosphorous moieties.
Abstract translation: 本文描述的是包含手性磷部分的核酸前药和核酸前药。 本文还描述了制备和使用包含手性磷部分的核酸前药和核酸前药的方法。
-
公开(公告)号：US10450568B2
公开(公告)日：2019-10-22
申请号：US16139091
申请日：2018-09-23
Applicant: WAVE LIFE SCIENCES LTD.
Inventor： David Charles Donnell Butler , Sethumadhavan Divakaramenon , Christopher J. Francis , Maria David Frank-Kamenetsky , Naoki Iwamoto , Genliang Lu , Subramanian Marappan , Meena , Chandra Vargeese , Gregory L. Verdine , Hailin Yang , Jason Jingxin Zhang
IPC: A61K31/712 , A61K31/7125 , C12N15/113 , C07H21/02 , C07H21/00 , A61P25/14 , A61P21/00 , A61K31/7115 , A61K48/00 , A61P27/00 , C07F9/59
Abstract: Among other things, the present disclosure relates to designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide altered splicing of a transcript. In some embodiments, provided oligonucleotide compositions have low toxicity. In some embodiments, provided oligonucleotide compositions provide improved protein binding profiles. In some embodiments, provided oligonucleotide compositions have improved delivery. In some embodiments, provided oligonucleotide compositions have improved uptake. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions.
-
公开(公告)号：US10307434B2
公开(公告)日：2019-06-04
申请号：US15167669
申请日：2016-05-27
Applicant: WAVE LIFE SCIENCES LTD.
Inventor： Gregory L. Verdine , Meena , Naoki Iwamoto
Abstract: Described herein are nucleic acid prodrugs and nucleic acid prodrugs comprising chiral phosphorous moieties. Also described herein are methods of making and using nucleic acid prodrugs and nucleic acid prodrugs comprising chiral phosphorous moieties.
-
公开(公告)号：US09885037B2
公开(公告)日：2018-02-06
申请号：US14414614
申请日：2013-07-12
Applicant: WAVE LIFE SCIENCES LTD.
Inventor： David Butler , Naoki Iwamoto , Meena , Nenad Svrzikapa , Gregory L. Verdine , Ivan Zlatev
IPC: C07H21/04 , C12N15/113 , C07H21/00 , C07C317/28 , C07D295/088 , C12Q1/68 , C12N15/11
Abstract: The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.
-
Patent Agency Ranking
公开(公告)号：US10590413B2
公开(公告)日：2020-03-17
申请号：US15462787
申请日：2017-03-17
Applicant: WAVE LIFE SCIENCES LTD.
Inventor： David Charles Donnell Butler , Naoki Iwamoto , Meena , Nenad Svrzikapa , Gregory L. Verdine , Ivan Zlatev
IPC: C12N15/113 , C07H21/00 , C07C317/28 , C07D295/088 , C12N15/11 , C12Q1/6876
Abstract: The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.
-
公开(公告)号：US10479995B2
公开(公告)日：2019-11-19
申请号：US15746220
申请日：2016-07-22
Applicant: WAVE LIFE SCIENCES LTD.
Inventor： Chandra Vargeese , Meena , Nenad Svrzikapa , Susovan Mohapatra , Christopher J. Francis , Gregory L. Verdine , Anna Sokolovska
IPC: C12N15/113 , C12N15/115 , A61P25/28
Abstract: Among other things, the present disclosure relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer. In some embodiments, a chirally controlled oligonucleotide composition has any sequence of bases, and/or pattern or base modifications, sugar modifications, backbone modifications and/or stereochemistry, or combination of these elements, described herein.
-
公开(公告)号：US10160969B2
公开(公告)日：2018-12-25
申请号：US15112146
申请日：2015-01-16
Applicant: WAVE LIFE SCIENCES LTD.
Inventor： Meena , David Butler , Naoki Iwamoto , Nenad Svrzikapa , Gregory L. Verdine , Ivan Zlatev
IPC: C12N15/113
Abstract: The present invention relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer.
-
公开(公告)号：US20170029457A1
公开(公告)日：2017-02-02
申请号：US15222910
申请日：2016-07-28
Applicant: WAVE LIFE SCIENCES LTD.
Inventor： Gregory L. Verdine , Meena , Naoki Iwamoto , David Charles Donnell Butler
IPC: C07H21/04
CPC classification number: C07H21/04 , A61K31/66 , A61K31/70 , C07C309/66 , C07D295/108 , C07H13/04
Abstract: Described herein are methods for the synthesis of derivatives of thiosulfonate reagents. Said reagents have utility for the synthesis of phosphorothiotriesters from H-phosphonates in a stereospecific fashion.
Abstract translation: 本文描述了合成硫代磺酸盐试剂衍生物的方法。 所述试剂可用于以立体特异性方式从H-膦酸盐合成磷酰化产物。
-
公开(公告)号：US20240117347A1
公开(公告)日：2024-04-11
申请号：US18062422
申请日：2022-12-06
Applicant: WAVE LIFE SCIENCES LTD.
Inventor： David Charles Donnell Butler , Sethumadhavan Divakaramenon , Christopher J. Francis , Maria David Frank-Kamenetsky , Naoki Iwamoto , Genliang Lu , Subramanian Marappan , Meena , Chandra Vargeese , Gregory L. Verdine , Hailin Yang , Jason Jingxin Zhang
IPC: C12N15/113 , A61K31/7115 , A61K31/712 , A61K31/7125 , A61K48/00 , A61P21/00 , A61P25/14 , A61P27/00 , C07F9/59 , C07H21/00 , C07H21/02
CPC classification number: C12N15/113 , A61K31/7115 , A61K31/712 , A61K31/7125 , A61K48/0016 , A61K48/0066 , A61K48/0083 , A61P21/00 , A61P25/14 , A61P27/00 , C07F9/59 , C07H21/00 , C07H21/02 , C12N2310/11 , C12N2310/315 , C12N2310/322 , C12N2310/343 , C12N2310/346 , C12N2320/33
Abstract: Among other things, the present disclosure relates to designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide altered splicing of a transcript. In some embodiments, provided oligonucleotide compositions have low toxicity. In some embodiments, provided oligonucleotide compositions provide improved protein binding profiles. In some embodiments, provided oligonucleotide compositions have improved delivery. In some embodiments, provided oligonucleotide compositions have improved uptake. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions.
-
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.067 seconds)
